Mon, May 5, 8:03 PM (6 days ago)
**Pfizer Inc. (PFE) Q1 2025 Financial Summary** **Financial Performance:** - **Revenue:** $13.7 billion, down 8% YoY due to a 6% operational decrease and a 2% unfavorable foreign exchange impact. - **Net Income:** $2.97 billion, down from $3.13 billion YoY. - **EPS:** $0.52, down from $0.55 YoY. - **Operating Cash Flow:** $2.34 billion, up from $1.09 billion YoY. **Segment Performance:** - **Biopharma:** Revenue of $13.4 billion, down 8% YoY. Key products include Eliquis, Prevnar, Comirnaty, and Paxlovid. - **Pfizer CentreOne:** Revenue of $257 million, up 2% YoY. - **Pfizer Ignite:** Revenue of $17 million, no change YoY. **Product Performance:** - **Eliquis:** $1.92 billion, down 4% operationally. - **Prevnar:** $1.66 billion, down 1% operationally. - **Comirnaty:** $565 million, up 62% operationally. - **Paxlovid:** $491 million, down 75% operationally. - **Xtandi:** $458 million, up 9% operationally. **Costs and Expenses:** - **Cost of Sales:** $2.85 billion, down 16% YoY. - **Selling, Informational, and Administrative Expenses:** $3.03 billion, down 13% YoY. - **Research and Development Expenses:** $2.20 billion, down 12% YoY. - **Restructuring Charges:** $678 million, up significantly YoY. **Cash Flow and Liquidity:** - **Operating Activities:** $2.34 billion, up from $1.09 billion YoY. - **Investing Activities:** $3.27 billion, up from $1.73 billion YoY. - **Financing Activities:** -$5.23 billion, down from -$4.93 billion YoY. **Outlook and Uncertainties:** - **COVID-19 Impact:** Continued investment in COVID-19 vaccines and treatments, with expectations of seasonal demand. - **Regulatory Environment:** Ongoing pricing pressures and regulatory challenges, including the Inflation Reduction Act. - **Product Supply:** Monitoring potential supply chain disruptions and raw material availability. - **Legal and Environmental Contingencies:** Ongoing legal proceedings and environmental remediation activities. **Future Operations:** - **Cost Reduction Initiatives:** Continuing cost realignment and manufacturing optimization programs to achieve savings. - **Capital Allocation:** Focus on dividend growth, share repurchases, and strategic investments. - **Product Development:** Ongoing R&D efforts and pipeline advancements, including new drug candidates and indications. **Ticker:** PFE